Company profile: IGeneX
1.1 - Company Overview
Company description
- Provider of diagnostic solutions for tick-borne diseases, offering culture enhanced PCR, PCR, serology, ImmunoBlots, and FISH tests for Lyme disease, Bartonella, Babesia, and tick-borne relapsing fever, plus tick testing for pathogen detection and training services; engaged in research and development of tests that accurately detect these pathogens.
Products and services
- Lyme Disease Testing: Multi-assay clinical-grade diagnostics combining ImmunoBlots, PCR, and serology to detect Lyme disease pathogens and patient antibodies from clinical samples, supporting comprehensive tick-borne infection assessment
- Culture Enhanced PCR (cePCR): Culture-based laboratory method that first cultures patient samples to promote tick-borne pathogen growth, then uses PCR to identify the pathogens causing disease
- Tick-Borne Relapsing Fever (TBRF) Testing: Molecular-diagnostic assays employing ImmunoBlots and PCR to detect TBRF pathogens in patient specimens for targeted identification of relapsing fever infections
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IGeneX
Spero Therapeutics
HQ: United States
Website
- Description: Provider of oral and IV antibiotic therapies for gram-negative infections: Tebipenem HBr for complicated urinary tract infections and acute pyelonephritis to reduce hospitalizations and support transition from IV to home care; SPR720, an oral investigational agent for nontuberculous mycobacterial pulmonary disease; and SPR206, an IV candidate for multidrug-resistant Gram-negative infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spero Therapeutics company profile →
Pherecydes Pharma
HQ: France
Website
- Description: Provider of innovative biotechnology focused on developing personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and has launched a multicenter European phage therapy trial to evaluate treatment on infected burn wounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pherecydes Pharma company profile →
Revagenix
HQ: United States
Website
- Description: Provider of infectious disease therapeutics, including a late-preclinical broad-spectrum antimicrobial for cUTI, HABP, VABP, neonatal sepsis and BSI; a novel agent to reduce care burden in chronic pulmonary infections; a treatment with a novel mechanism for challenging Gram-negative infections; and an on-hold pipeline of Gram-negative antibacterials that can be activated within 12-18 months.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revagenix company profile →
ISR Immune System Regulation
HQ: Sweden
Website
- Description: Provider of innovation-driven immunotherapy research, conducting preclinical and clinical studies to develop novel drugs for curative treatment of viral infections, based at the Karolinska Hospital in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ISR Immune System Regulation company profile →
BioAegis Therapeutics
HQ: United States
Website
- Description: Provider of plasma gelsolin-based therapeutics for infectious, inflammatory and degenerative diseases. Offers recombinant human plasma gelsolin (rhu-pGSN) to restore depleted levels, regulate inflammation and enhance immune response without immunosuppression; ARDS treatment; host-directed therapeutics; >40-patent IP; clinical trials and research collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAegis Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IGeneX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IGeneX
2.2 - Growth funds investing in similar companies to IGeneX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IGeneX
4.2 - Public trading comparable groups for IGeneX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →